Indwelling Pleural Catheters with or Without Doxycycline in Treating Patients with Malignant Pleural Effusions

Description

This study is designed to obtain preliminary data comparing indwelling pleural catheters (IPCs) versus IPCs plus doxycycline for pleurodesis as treatments for malignant pleural effusion (MPE). Indwelling pleural catheters (IPCs) are commonly used to treat pleural effusions (build-up of fluid in the lungs). Doxycycline is an antibiotic that is also used to treat pleural effusions. The goal of this clinical research study is to learn if adding doxycycline to the use of an IPC can lead to shorter treatment times with IPCs.

Conditions

Pleural Neoplasm

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is designed to obtain preliminary data comparing indwelling pleural catheters (IPCs) versus IPCs plus doxycycline for pleurodesis as treatments for malignant pleural effusion (MPE). Indwelling pleural catheters (IPCs) are commonly used to treat pleural effusions (build-up of fluid in the lungs). Doxycycline is an antibiotic that is also used to treat pleural effusions. The goal of this clinical research study is to learn if adding doxycycline to the use of an IPC can lead to shorter treatment times with IPCs.

A Prospective Observational Cohort Study of Indwelling Pleural Catheters Versus Indwelling Pleural Catheters Plus Doxycycline Pleurodesis for Treatment of Malignant Pleural Effusions

Indwelling Pleural Catheters with or Without Doxycycline in Treating Patients with Malignant Pleural Effusions

Condition
Pleural Neoplasm
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Outpatients with MPE undergoing IPC placement
  • * Sufficient mental capacity to provide informed consent and answer Short-Form Six-Dimension health index (SF-6D) and Borg score questions
  • * Inpatients that are expected to be discharged within 5 days of receiving an indwelling pleural catheter
  • * Patients undergoing pleurodesis for benign disease (e.g., spontaneous pneumothorax)
  • * Inability or unwillingness to give informed consent
  • * Inability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)
  • * Pregnancy
  • * Previous intrapleural therapy for MPE on the same side
  • * Eastern Cooperative Oncology Group (ECOG) of 4 and life expectancy =\< 2 weeks
  • * Doxycycline allergy
  • * Extensive loculations or hydropneumothorax or other contraindication to pleurodesis
  • * Chylous effusions associated with malignant disease

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

David Ost, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2025-04-30